Cigna will remove Humira from its largest commercial formularies in 2025.
Express Scripts, Cigna Group's pharmacy benefit manager, will have several biosimilar alternatives to the biologic drug available through its formulary, according to an Aug. 23 news release.
A new Humira biosimilar is available at $0 for patients of Cigna's Accredo Specialty Pharmacy, according to the release, which said it can save patients up to $3,500 per year.
"With this latest update, we’re prepared to embrace the savings biosimilars offer and pave the way for access to the next wave of prescription drug blockbusters coming down the pike," Adam Kautzner, president of Evernorth Care Management and Express Scripts, said in the release.
Express Scripts is the second major PBM to replace Humira with its biosimilar competitors. CVS Caremark replaced Humira with biosimilars from its main formularies April 1.
Humira, used to treat rheumatoid arthritis and other inflammatory conditions, is the highest-grossing drug of all time.